Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants - IM037-009

Updated: 11 September, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 21-65

    Age Range

  • 1

    Location(s)

  • Not Yet Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Part A SAD Cohort A2
Drug: BMS-986337 Other: BMS-986337 Placebo
Experimental: Part A SAD Cohort A3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A4
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A5
Drug: BMS-986337 Other: BMS-986337 Placebo
Experimental: Part A SAD Cohort A6
Biological: Famotidine Drug: BMS-986337
Experimental: Part A Single Ascending Dose (SAD) Cohort A1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B4
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B Multiple Ascending Dose (MAD) Cohort B1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C3
Other: BMS-986337 Placebo Drug: BMS-986337

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations - For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not living outside of Japan for more than 10 years, and both parents are ethnically Japanese) - Body mass index (BMI) of 18.0 kg/m^2 to 30.0 kg/m^2, inclusive, at screening; BMI = weight (kg)/height (m)^2 - Women and men must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women who are of childbearing potential - Women who are breastfeeding - Prior exposure to BMS-986278 - Positive nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -2 Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com